An experimental drug for OCD

The study seeks to explore the benefits of an experimental drug as a potential new treatment of obsessive-compulsive disorder (OCD).  The experimental drug changes activity in brain areas believed to be involved in OCD. 

This study will involve approximately 8-10 weeks of study participation, including eight weeks of investigational treatment.

Study phase: I

Basic eligibility criteria:
Please contact the study coordinator for additional eligibility information.

Aged 21 to 65 years old, 
Must have moderate to severe Obsessive-Compulsive Disorder (OCD), 
Must have failed at least one routine care treatment, 

Women who are pregnant or breastfeeding are not eligible.

Primary disease category: Mental Health

Secondary disease categories: Mental Health

This study is enrolling healthy volunteers.

Protocol number: 1707613822

Projected enrollment dates: April 2019 to December 2020

Official study title: Experimental Treatment of Obsessive Compulsive Disorder